Genes Reveal Drug Risks: India's New Health Frontier

Pharmacogenomic testing, a field examining how an individual's genes influence their response to medications, is transitioning from academic research to clinical practice in India. Specialists at prominent hospitals are utilizing these tests to guide high-stakes treatment decisions, although widespread adoption remains limited. The technology's potential was illustrated by a patient whose genetic report revealed an inability to convert folic acid into its active form, leading to a successful switch to methylfolate therapy and normalization of homocysteine levels.

Despite the clinical value, barriers such as the high cost of standalone tests (₹15,000 to ₹35,000), a lack of comprehensive awareness among practitioners and patients, and lengthy turnaround times impede its routine use. Integrated panels, like one from PreventiveHealth.ai, aim to address these by combining blood markers, pharmacogenomic analysis for over 200 medications, and whole-genome sequencing into a single investigation, offering a "once-in-a-lifetime" genetic profile.

The Indian genomic testing market is experiencing significant growth, valued at USD 550 million and expanding at approximately 18% annually, with major industry players entering the space. Clinicians emphasize that pharmacogenomic testing offers substantial clinical value for patients on chronic medications, those with a strong family history of diseases like cancer or cardiovascular conditions, or individuals commencing long-term therapies like statins or antidepressants. The effective use of this information hinges on a collaborative approach between physician and patient to interpret and act upon the genetic findings.